BCAL Diagnostics (ASX:BDX) EV-to-Revenue : (As of Jun. 06, 2024)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, BCAL Diagnostics's enterprise value is A$31.81 Mil. BCAL Diagnostics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil. Therefore, BCAL Diagnostics's EV-to-Revenue for today is .

The historical rank and industry rank for BCAL Diagnostics's EV-to-Revenue or its related term are showing as below:

ASX:BDX's EV-to-Revenue is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 3.085
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-06), BCAL Diagnostics's stock price is A$0.125. BCAL Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00. Therefore, BCAL Diagnostics's PS Ratio for today is .

BCAL Diagnostics EV-to-Revenue Historical Data

The historical data trend for BCAL Diagnostics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics EV-to-Revenue Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

EV-to-Revenue

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of BCAL Diagnostics's EV-to-Revenue

For the Diagnostics & Research subindustry, BCAL Diagnostics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's EV-to-Revenue falls into.

BCAL Diagnostics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

BCAL Diagnostics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	31.807	/	0
	=

BCAL Diagnostics's current Enterprise Value is A$31.81 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BCAL Diagnostics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

BCAL Diagnostics (ASX:BDX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

BCAL Diagnostics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.125	/	0
	=

BCAL Diagnostics's share price for today is A$0.125.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

BCAL Diagnostics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.